ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 639

Examination Of The Cytokine Profile Of The Cerebrospinal Fluid In Neuropsychiatric Systemic Lupus Erythematosus

Kunihiro Ichinose1, Takeshi Ushigusa2, Yoshikazu Nakashima3, Takahisa Suzuki3, Yoshiro Horai4, Shin-ya Kawashiri2, Naoki Iwamoto2, Mami Tamai3, Kazuhiko Arima4, Hideki Nakamura2, Tomoki Origuchi5 and Atsushi Kawakami4, 1Department of Immunology and Rheumatology, Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 2Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 3Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 4Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 5Department of Health Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: central nervous system involvement, cytokines, Diagnostic Tests, pathogenesis and systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Title: Systemic Lupus Erythematosus - Human Etiology and Pathogenesis: Mechanisms and Biomarkers

Session Type: Abstract Submissions (ACR)

Examination of the cytokine profile of the cerebrospinal fluid in neuropsychiatric systemic lupus erythematosus

Background/Purpose: Neuropsychiatric systemic lupus erythematosus (NPSLE) is a serious complication in systemic lupus erythematosus (SLE). NPSLE syndromes involve both the central and peripheral nervous systems. Despite advances in the understanding of the immunopathogenic and clinical aspects of SLE, NPSLE remains a diagnostic and therapeutic challenge.

Methods: We examined the cytokine profile in the cerebrospinal fluid (CSF) of NPSLE patients admitted to our hospital in a 7-year period from 2006 through 2012 and searched for markers that may be useful for the diagnosis of NPSLE. We used the CSF of patients with multiple sclerosis (MS) or neuromyelitis optica (NMO) as a disease control group. We examined 27 types of cytokine, chemokines, and growth factors in the NPSLE group (n=27), MS group (n=10) and NMO group (n=10) using Bio-Plex Pro assays.

Results: All of the NPSLE patients were women. The mean ± SD disease duration of NPSLE was 10.6±9.56 years. The NPSLE patients’ Safety of Estrogens in Lupus Erythematosus National Assessment–Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) score was 13.3±5.86, and their anti-ds-DNA antibody level was 23.3±58.6 U/mL. The percentages of anti-phospholipid antibody syndrome, anti-ribosomal P antibody positivity, and abnormality of brain MRI were 4/27 (14.8%), 5/27 (18.5%) and 9/27 (33.3%), respectively. Aside from the cytokines that are known to be related to NPSLE such as interleukin (IL)-6, the concentrations of basic FGF, and IL-1ra, -5, -7, -9, -15 and -17 were significantly higher in the NPSLE group compared to the other two groups. A multivariate analysis revealed that the protein levels of IL-5 (p<0.036), IL-9 (p<0.0005), IL-15 (

Conclusion: In NPSLE patients who do not show IL-6 elevation, it might be advisable to examine other cytokines. The determination of various types of CSF cytokine profiles may contribute to the diagnosis of NPSLE and may help elucidate the mechanisms underlying this disease.


Disclosure:

K. Ichinose,
None;

T. Ushigusa,
None;

Y. Nakashima,
None;

T. Suzuki,
None;

Y. Horai,
None;

S. Y. Kawashiri,
None;

N. Iwamoto,
None;

M. Tamai,
None;

K. Arima,
None;

H. Nakamura,
None;

T. Origuchi,
None;

A. Kawakami,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/examination-of-the-cytokine-profile-of-the-cerebrospinal-fluid-in-neuropsychiatric-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology